Sonodynamic-Chemoradiotherapy Integration in Glioblastoma

Inclusion Criteria: 1. Signed informed consent form; 2. Age \< 75 years; 3. Newly diagnosed postoperative glioblastoma patients pathologically confirmed as glioblastoma; 4. Absence of severe hematopoietic dysfunction or cardiac, pulmonary, hepatic, renal abnormalities, or immunodeficiency. Pre-enrollment laboratory results must meet the following: * Hematology: * White blood cell count ≥4×10⁹/L * Absolute neutrophil count ≥1.5×10⁹/L * Platelets ≥100×10⁹/L * Hemoglobin ≥90g/L * Renal function: * Serum creatinine ≤1.2mg/dL or creatinine clearance ≥60mL/min * Hepatic function: * Total bilirubin ≤1.5×ULN (≤3.0×ULN if liver metastasis present) * AST/ALT ≤2.0×ULN (≤5.0×ULN if liver metastasis present) * Coagulation: * INR ≤2.0, with PT, APTT, and TT within normal ranges; 5. Life expectancy ≥3 months; 6. Adverse reactions from prior anti-tumor therapy recovered to ≤ Grade 1, or complete recovery from surgery (Investigator's judgment); 7. Fertile females and all male subjects must agree to use highly effective contraception (condoms, sponges, gels, diaphragms, IUDs, oral/injectable contraceptives, or implants) during the trial and for 12 months after last Hematoporphyrin use. Fertile females must have negative pregnancy test within ≤7 days before investigational product administration. Exclusion Criteria: 1. Recurrent glioblastoma, brainstem tumors, or glioblastoma patients having received postoperative chemoradiotherapy; 2. Hypersensitivity to photosensitizers; 3. Uncontrolled infections, refractory epilepsy, and/or intracranial hypertension, and/or hypertension, and/or hyperglycemia; 4. HIV infection, active hepatitis B (HBsAg positive with HBV DNA positive), or hepatitis C (HCV antibody positive); 5. Other malignancies within 5 years without effective control (excluding cervical carcinoma in situ, cutaneous squamous cell carcinoma, or localized basal cell skin cancer); 6. Other Investigator-assessed contraindications for trial participation.